galeterone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Galeterone is a steroidal antiandrogen which was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique triple mechanism of action, acting as an androgen receptor antagonist, androgen receptor down regulator, and CYP17A1 inhibitor, the latter of which prevents the biosynthesis of androgens. As a CYP17A1 inhibitor, galeterone shows selectivity for 17,20-lyase over 17α-hydroxylase.   Wikipedia

Chemistry

  • SMILES: C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2n5cnc6ccccc56
  • InChIKey: PAFKTGFSEFKSQG-PAASFTFBSA-N
  • Mol. Mass: 388.56
  • ALogP: 5.81
  • ChEMBL Molecule:
    galeterone  
More Chemistry

Pharmacology

Alternative names

17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3beta-ol | 3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene | 3-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene | galeterone | tok-001 | vn/124 | vn-124-1 | vn/124-1

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Healthy Volunteers (Phase 1)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue